https://doi.org/10.31288/oftalmolzh201751520

Character of meibomian gland dysfunction in patients with diabetic polyneuropathy with severe complications

P.A. Bezdetko, L.I. Ivzhenko

Kharkiv National Medical University

Kharkiv (Ukraine)

E-mail: ludok26@yandex.ru            

Background. Meibomian gland dysfunction (MGD) is a chronic, diffuse abnormality of the meibomian glands, commonly characterized by terminal duct obstruction and/or qualitative/quantitative changes in the glandular secretion. Diabetic polyneuropathy can be a cause of MGD.

Purpose: To improve the efficacy of diagnosis of MGD in patients with severe complications of diabetic polyneuropathy.

Materials and Methods: Standard ophthalmological examination, the Schirmer’s test before and 2 hours after eyelid compression, the Norn’s test, the OPI test, a compression test, an IVAD test, contact meibography with green filter were performed. Severe complications of diabetic polyneuropathy (N3 stage) were recorded in 25 patients (50 eyes). A control group consisted of 97 persons (194 eyes) without diabetes.

Results and Discussion: The Schirmer’s test was 2.7 times reduced in patients with N3 stage (4.83 mm) in comparison with that in the control group (12.82) (p<0.001). The Norn’s test was 4.8 times lower in patients with N3-stage (3.45 sec) than in patients without diabetes (9.48 sec) (p<0.001). The OPI test in patients with N3 stage was 1.9 times lower than that in the control group, (p<0.001). The Schirmer’s test in patients with N3 were 1.2 times higher after compression than before it (p<0.05). According to meibography, in patients with N3, loss area of the meibomian glands corresponded to stage 4.

Conclusions: The patients with stage N3 had MGD stage 3 (44 %) and 4 (40 %), while the first stage of MGD was not identified in any patient.

Key-words: meibomian glands dysfunction, diabetic polyneuropathy, Schirmer’s test, contact meibography, meibomian gland secretions   

References

1.      Blackie CA, Korb DR. The diurnal secretory characteristics in individual meibomian glands. Cornea. 2009;29:34–38
Crossref   Pubmed

2.      Blackie CA, Korb DR. Recovery time of an optimally secreting meibomian gland. Cornea. 2009;28:293–297.
Crossref   Pubmed

3.      Bron AJ, Benjamin L, Snibson G. Meibomian gland disease. Classification and grading of lid changes. Eye. 1991;5:395-411.
Crossref   Pubmed

4.      Boulton JM, Malik RA, Arezzo JC. Diabetic Somatic Neuropathies. Diabetes Care. 2004;27(6):1458-86.
Crossref   Pubmed

5.      Feldman EL. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. J. Clinic. Investigation. 2003;111:431-3.
Crossref   Pubmed

6.      Foulks G, Bron A. A clinical description of meibomian gland dysfunction. Ocul Surf. 2003;107-26.
Crossref   Pubmed

7.      Jester JV, Nicolaides N, Smith RE. Meibomian gland studies: histologic and ultrastructural investigations. Invest Ophthalmol Vis Sci. 1981;20:537-47.

8.      Kelly K Nichols. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. IOVS, Special Issue. 2011;52 (4).
Crossref   Pubmed

9.      Kozak I, Bron AJ, Kucharova K. Morphologic and volumetric studies of the meibomian glands in elderly human eyelids. Corne. 2007;26:610-4.
Crossref   Pubmed

10.  Nelson JD, Shimazaki J, Benitez-del-Castillo JM et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011;52:1930–7.
Crossref   Pubmed

11.  Ousler GW 3rd1, Hagberg KW, Schindelar M, Welch D, Abelson M. The Ocular Protection Index. Cornea. 2008;Jun; 27(5):509-13.
Crossref   Pubmed

12.  Pflugfelder SC, Tseng S, Sanabria O et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea. 1998;17:38-56.
Crossref   Pubmed

13.  Pult H Meiboscale. Dr Heiko Pult. Optometry & Vision Research. 2015; Accessed February 10.
Crossref

14.  Tomlinson A, Bron AJ, Korb DR et al. The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee. Invest Ophthalmol Vis Sci. 2011;52:2006-49. 
Crossref   Pubmed